| Year |
Citation |
Score |
| 2023 |
Conti G, Bärenwaldt A, Rabbani S, Sarcevic M, Jiang X, Schwardt O, Ricklin D, Pieters RJ, Läubli H, Ernst B, Mühlethaler T. Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation. Angewandte Chemie (International Ed. in English). e202314280. PMID 37947772 DOI: 10.1002/anie.202314280 |
0.519 |
|
| 2022 |
Bechtler C, Koutsogiannaki S, Umnyakova E, Hamid A, Gautam A, Sarigiannis Y, Pouw RB, Lamers C, Rabbani S, Schmidt CQ, Lambris JD, Ricklin D. Complement-regulatory biomaterial coatings: activity and selectivity profile of the factor H-binding peptide 5C6. Acta Biomaterialia. PMID 36328123 DOI: 10.1016/j.actbio.2022.10.055 |
0.344 |
|
| 2020 |
Kroezen B, Conti G, Girardi B, Cramer J, Jiang X, Rabbani S, Müller J, Kokot M, Luisoni E, Ricklin D, Schwardt O, Ernst B. A Potent Mimetic of the Siglec-8 Ligand 6'-Sulfo-Sialyl Lewisx. Chemmedchem. PMID 32744401 DOI: 10.1002/Cmdc.202000417 |
0.558 |
|
| 2020 |
Hughes S, Gumas J, Lee R, Romano M, Berger N, Gautam AK, Sfyroera G, Chan AL, Gnanaguru G, Connor KM, Kim BJ, Dunaief JL, Ricklin D, Hajishengallis G, Yancopoulou D, et al. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology (Orlando, Fla.). 108391. PMID 32229292 DOI: 10.1016/J.Clim.2020.108391 |
0.362 |
|
| 2019 |
Ricklin D, Mastellos DC, Lambris JD. Therapeutic targeting of the complement system. Nature Reviews. Drug Discovery. PMID 31819218 DOI: 10.1038/S41573-019-0055-Y |
0.37 |
|
| 2019 |
Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nature Reviews. Drug Discovery. PMID 31324874 DOI: 10.1038/S41573-019-0031-6 |
0.354 |
|
| 2019 |
Baas I, Delvasto-Nuñez L, Ligthart P, Brouwer C, Folman C, Reis ES, Ricklin D, Lambris JD, Wouters D, de Haas M, Jongerius I, Zeerleder SS. Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica. PMID 31171642 DOI: 10.3324/Haematol.2019.216028 |
0.354 |
|
| 2019 |
Lombardi E, Matte A, Risitano AM, Ricklin D, Lambris JD, De Zanet D, Jokiranta ST, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, et al. Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica. 104: 919-928. PMID 30630982 DOI: 10.3324/Haematol.2018.198622 |
0.326 |
|
| 2018 |
Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Molecular Immunology. PMID 30121124 DOI: 10.1016/J.Molimm.2018.06.008 |
0.358 |
|
| 2018 |
van Griensven M, Ricklin D, Denk S, Halbgebauer R, Braun CK, Schultze A, Hönes F, Koutsogiannaki S, Primikyri A, Reis E, Messerer D, Hafner S, Radermacher P, Biglarnia AR, Resuello RRG, et al. Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. Shock (Augusta, Ga.). PMID 29461464 DOI: 10.1097/Shk.0000000000001127 |
0.358 |
|
| 2018 |
Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nature Reviews. Nephrology. 14: 26-47. PMID 29199277 DOI: 10.1038/Nrneph.2017.156 |
0.362 |
|
| 2018 |
Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nature Reviews. Immunology. 18: 5-18. PMID 28920587 DOI: 10.1038/Nri.2017.97 |
0.34 |
|
| 2017 |
Blatt AZ, Saggu G, Cortes C, Herbert AP, Kavanagh D, Ricklin D, Lambris JD, Ferreira VP. Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. Frontiers in Immunology. 8: 1586. PMID 29218045 DOI: 10.3389/Fimmu.2017.01586 |
0.329 |
|
| 2017 |
Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD. Novel mechanisms and functions of complement. Nature Immunology. 18: 1288-1298. PMID 29144501 DOI: 10.1038/Ni.3858 |
0.35 |
|
| 2017 |
Wang H, Ricklin D, Lambris JD. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proceedings of the National Academy of Sciences of the United States of America. PMID 28973891 DOI: 10.1073/Pnas.1707364114 |
0.302 |
|
| 2017 |
Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nature Structural & Molecular Biology. PMID 28671664 DOI: 10.1038/Nsmb.3427 |
0.356 |
|
| 2017 |
Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Molecular Immunology. 89: 10-21. PMID 28576323 DOI: 10.1016/J.Molimm.2017.05.013 |
0.366 |
|
| 2017 |
Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology. PMID 28416449 DOI: 10.1016/J.It.2017.03.003 |
0.37 |
|
| 2017 |
Papanastasiou M, Koutsogiannaki S, Sarigiannis Y, Geisbrecht BV, Ricklin D, Lambris JD. Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. Journal of Immunology (Baltimore, Md. : 1950). PMID 28258193 DOI: 10.4049/Jimmunol.1601864 |
0.359 |
|
| 2017 |
Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood. 129: 970-980. PMID 28028023 DOI: 10.1182/Blood-2016-08-732800 |
0.415 |
|
| 2016 |
Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunological Reviews. 274: 33-58. PMID 27782325 DOI: 10.1111/Imr.12500 |
0.411 |
|
| 2016 |
Ricklin D, Lambris JD. Preformed mediators of defense-Gatekeepers enter the spotlight. Immunological Reviews. 274: 5-8. PMID 27782322 DOI: 10.1111/Imr.12497 |
0.305 |
|
| 2016 |
Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. Immunological Reviews. 274: 152-171. PMID 27782321 DOI: 10.1111/Imr.12475 |
0.367 |
|
| 2016 |
Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP. Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology (Orlando, Fla.). PMID 27546448 DOI: 10.1016/J.Clim.2016.08.017 |
0.369 |
|
| 2016 |
Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology. 221: 1046-57. PMID 27353192 DOI: 10.1016/J.Imbio.2016.06.013 |
0.423 |
|
| 2016 |
Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Seminars in Immunology. PMID 27321574 DOI: 10.1016/J.Smim.2016.06.001 |
0.395 |
|
| 2016 |
Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nature Reviews. Nephrology. 12: 383-401. PMID 27211870 DOI: 10.1038/Nrneph.2016.70 |
0.384 |
|
| 2016 |
Blatt AZ, Saggu G, Kulkarni KV, Cortes C, Thurman JM, Ricklin D, Lambris JD, Valenzuela JG, Ferreira VP. Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. Journal of Immunology (Baltimore, Md. : 1950). 196: 4671-80. PMID 27183616 DOI: 10.4049/Jimmunol.1600040 |
0.343 |
|
| 2016 |
Hajishengallis G, Hajishengallis E, Kajikawa T, Wang B, Yancopoulou D, Ricklin D, Lambris JD. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Seminars in Immunology. PMID 27021500 DOI: 10.1016/J.Smim.2016.03.006 |
0.383 |
|
| 2016 |
Forneris F, Wu J, Xue X, Ricklin D, Lin Z, Sfyroera G, Tzekou A, Volokhina E, Granneman JC, Hauhart R, Bertram P, Liszewski MK, Atkinson JP, Lambris JD, Gros P. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. The Embo Journal. PMID 27013439 DOI: 10.15252/Embj.201593673 |
0.363 |
|
| 2016 |
Schmidt CQ, Harder MJ, Nichols EM, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi ÁI, Uzonyi B, Pappworth IY, Ricklin D, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology. 221: 503-11. PMID 26792457 DOI: 10.1016/J.Imbio.2015.12.009 |
0.44 |
|
| 2016 |
Maekawa T, Briones RA, Resuello RR, Tuplano JV, Hajishengallis E, Kajikawa T, Koutsogiannaki S, Garcia CA, Ricklin D, Lambris JD, Hajishengallis G. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. Journal of Clinical Periodontology. 43: 238-49. PMID 26728318 DOI: 10.1111/Jcpe.12507 |
0.348 |
|
| 2016 |
Ricklin D, Lambris JD. Therapeutic control of complement activation at the level of the central component C3. Immunobiology. 221: 740-6. PMID 26101137 DOI: 10.1016/J.Imbio.2015.06.012 |
0.433 |
|
| 2016 |
Harder MJ, Anliker M, Reis ES, Huber-Lang M, Schrezenmeier H, Höchsmann B, von Zabern I, Simmet T, Ricklin D, Lambris JD, Schmidt CQ. Evaluation of factor H (FH), miniFH and the Fc-fusion protein Fc-miniFH in pharmacokinetic studies and different in vitro models of complement mediated diseases Immunobiology. 221: 1217-1218. DOI: 10.1016/J.Imbio.2016.06.206 |
0.303 |
|
| 2016 |
Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ. Mechanistic evidence for incomplete terminal pathway inhibition under eculizumab during strong complement activation Immunobiology. 221: 1216. DOI: 10.1016/J.Imbio.2016.06.204 |
0.329 |
|
| 2015 |
Harder MJ, Anliker M, Höchsmann B, Simmet T, Huber-Lang M, Schrezenmeier H, Ricklin D, Lambris JD, Barlow PN, Schmidt CQ. Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. Journal of Immunology (Baltimore, Md. : 1950). PMID 26643478 DOI: 10.4049/Jimmunol.1501919 |
0.415 |
|
| 2015 |
Wang J, Wang L, Xiang Y, Ricklin D, Lambris JD, Chen G. Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clinical Immunology (Orlando, Fla.). PMID 26548839 DOI: 10.1016/J.Clim.2015.11.002 |
0.402 |
|
| 2015 |
Georgoutsou-Spyridonos M, Ricklin D, Pratsinis H, Perivolioti E, Pirmettis I, Garcia BL, Geisbrecht BV, Foukas PG, Lambris JD, Mastellos DC, Sfyroera G. Attenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. Journal of Immunology (Baltimore, Md. : 1950). 195: 3946-58. PMID 26342032 DOI: 10.4049/Jimmunol.1500966 |
0.407 |
|
| 2015 |
Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD. Applying complement therapeutics to rare diseases. Clinical Immunology (Orlando, Fla.). 161: 225-40. PMID 26341313 DOI: 10.1016/J.Clim.2015.08.009 |
0.335 |
|
| 2015 |
Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Molecular Oral Microbiology. 31: 3-17. PMID 26332138 DOI: 10.1111/Omi.12129 |
0.422 |
|
| 2015 |
Hamad OA, Mitroulis I, Fromell K, Kozarcanin H, Chavakis T, Ricklin D, Lambris JD, Ekdahl KN, Nilsson B. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thrombosis and Haemostasis. 114: 1207-17. PMID 26293614 DOI: 10.1160/Th15-02-0162 |
0.39 |
|
| 2015 |
Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD, Ricklin D. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood. PMID 26082452 DOI: 10.1182/Blood-2015-02-625871 |
0.415 |
|
| 2015 |
Zhang Y, Shao D, Ricklin D, Hilkin BM, Nester CM, Lambris JD, Smith RJ. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology. 220: 993-8. PMID 25982307 DOI: 10.1016/J.Imbio.2015.04.001 |
0.418 |
|
| 2015 |
Sfyroera G, Ricklin D, Reis ES, Chen H, Wu EL, Kaznessis YN, Ekdahl KN, Nilsson B, Lambris JD. Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity. Journal of Immunology (Baltimore, Md. : 1950). 194: 3305-16. PMID 25712219 DOI: 10.4049/Jimmunol.1402781 |
0.371 |
|
| 2015 |
Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation. 45: 423-40. PMID 25678219 DOI: 10.1111/Eci.12419 |
0.438 |
|
| 2015 |
Reis ES, DeAngelis RA, Chen H, Resuello RR, Ricklin D, Lambris JD. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology. 220: 476-82. PMID 25468722 DOI: 10.1016/J.Imbio.2014.10.026 |
0.354 |
|
| 2015 |
Kourtzelis I, Ferreira A, Mitroulis I, Ricklin D, Bornstein SR, Waskow C, Lambris JD, Chavakis T. Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et MéTabolisme. 47: 36-42. PMID 25350518 DOI: 10.1055/S-0034-1390452 |
0.393 |
|
| 2014 |
Woehl JL, Stapels DA, Garcia BL, Ramyar KX, Keightley A, Ruyken M, Syriga M, Sfyroera G, Weber AB, Zolkiewski M, Ricklin D, Lambris JD, Rooijakkers SH, Geisbrecht BV. The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase. Journal of Immunology (Baltimore, Md. : 1950). 193: 6161-71. PMID 25381436 DOI: 10.4049/Jimmunol.1401600 |
0.411 |
|
| 2014 |
Mastellos DC, Ricklin D, Yancopoulou D, Risitano A, Lambris JD. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology. 7: 583-98. PMID 25213458 DOI: 10.1586/17474086.2014.953926 |
0.392 |
|
| 2014 |
Huang Y, Reis ES, Knerr PJ, van der Donk WA, Ricklin D, Lambris JD. Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. Chemmedchem. 9: 2223-6. PMID 25056114 DOI: 10.1002/Cmdc.201402212 |
0.387 |
|
| 2014 |
Maekawa T, Abe T, Hajishengallis E, Hosur KB, DeAngelis RA, Ricklin D, Lambris JD, Hajishengallis G. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. Journal of Immunology (Baltimore, Md. : 1950). 192: 6020-7. PMID 24808362 DOI: 10.4049/Jimmunol.1400569 |
0.343 |
|
| 2014 |
Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 123: 2094-101. PMID 24497537 DOI: 10.1182/Blood-2013-11-536573 |
0.394 |
|
| 2014 |
Klapper Y, Hamad OA, Teramura Y, Leneweit G, Nienhaus GU, Ricklin D, Lambris JD, Ekdahl KN, Nilsson B. Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials. 35: 3688-96. PMID 24462362 DOI: 10.1016/J.Biomaterials.2013.12.085 |
0.419 |
|
| 2014 |
Huang Y, Reis ES, Knerr PJ, van der Donk WA, Ricklin D, Lambris JD. Cover Picture: Conjugation to Albumin-Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin (ChemMedChem 10/2014) Chemmedchem. 9: 2209-2209. DOI: 10.1002/Cmdc.201490037 |
0.332 |
|
| 2013 |
Yang K, Dinasarapu AR, Reis ES, Deangelis RA, Ricklin D, Subramaniam S, Lambris JD. CMAP: Complement Map Database. Bioinformatics (Oxford, England). 29: 1832-3. PMID 23661693 DOI: 10.1093/Bioinformatics/Btt269 |
0.311 |
|
| 2013 |
Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. Journal of Immunology (Baltimore, Md. : 1950). 190: 5712-21. PMID 23616575 DOI: 10.4049/Jimmunol.1203548 |
0.425 |
|
| 2013 |
Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. Journal of Immunology (Baltimore, Md. : 1950). 190: 3839-47. PMID 23564578 DOI: 10.4049/Jimmunol.1203200 |
0.367 |
|
| 2013 |
Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. Journal of Immunology (Baltimore, Md. : 1950). 190: 3831-8. PMID 23564577 DOI: 10.4049/Jimmunol.1203487 |
0.376 |
|
| 2013 |
Kourtzelis I, Rafail S, DeAngelis RA, Foukas PG, Ricklin D, Lambris JD. Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 2768-76. PMID 23558338 DOI: 10.1096/Fj.12-225888 |
0.331 |
|
| 2013 |
Yang K, DeAngelis RA, Reed JE, Ricklin D, Lambris JD. Complement in action: an analysis of patent trends from 1976 through 2011. Advances in Experimental Medicine and Biology. 735: 301-13. PMID 23402036 DOI: 10.1016/J.Imbio.2012.08.081 |
0.378 |
|
| 2013 |
Garcia BL, Summers BJ, Ramyar KX, Tzekou A, Lin Z, Ricklin D, Lambris JD, Laity JH, Geisbrecht BV. A structurally dynamic N-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins. The Journal of Biological Chemistry. 288: 2870-81. PMID 23233676 DOI: 10.1074/Jbc.M112.426858 |
0.439 |
|
| 2013 |
Nilsson PH, Ekdahl KN, Magnusson PU, Qu H, Iwata H, Ricklin D, Hong J, Lambris JD, Nilsson B, Teramura Y. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials. 34: 985-94. PMID 23137394 DOI: 10.1016/J.Biomaterials.2012.10.040 |
0.319 |
|
| 2013 |
Yang K, Deangelis RA, Reed JE, Ricklin D, Lambris JD. Complement in Action: An Analysis of Patent Trends from 1976 Through 2011. Advances in Experimental Medicine and Biology. 735: 301-313. PMID 22990712 DOI: 10.1007/978-1-4614-4118-2_21 |
0.378 |
|
| 2013 |
Ricklin D, Lambris JD. Progress and Trends in Complement Therapeutics. Advances in Experimental Medicine and Biology. 735: 1-22. PMID 22990692 DOI: 10.1007/978-1-4614-4118-2_1 |
0.352 |
|
| 2013 |
Qu H, Ricklin D, Bai H, Chen H, Reis ES, Maciejewski M, Tzekou A, DeAngelis RA, Resuello RR, Lupu F, Barlow PN, Lambris JD. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology. 218: 496-505. PMID 22795972 DOI: 10.1016/J.Imbio.2012.06.003 |
0.393 |
|
| 2013 |
Ricklin D, Risitano AM, Reis ES, Ricci P, Huang Y, Lin Z, Chen H, Pascariello C, Raia M, Del Vecchio L, Pane F, Resuello RRG, DeAngelis RA, Lambris JD. Preclinical Development and In Vivo Evaluation Of Next-Generation Compstatin Analogs With Improved Systemic Profiles: A Novel Option For The Treatment Of Paroxysmal Nocturnal Hemoglobinuria Blood. 122: 1239-1239. DOI: 10.1182/Blood.V122.21.1239.1239 |
0.436 |
|
| 2013 |
Schmidt C, Lin Z, Risitano A, DeAngelis R, Simmet T, Ricklin D, Lambris J. Optimisation and evaluation of the next generation of triple-targeted immune inhibitors from the “mini-FH class” of engineered complement inhibitors Molecular Immunology. 56: 263-264. DOI: 10.1016/J.Molimm.2013.05.071 |
0.321 |
|
| 2012 |
Abe T, Hosur KB, Hajishengallis E, Reis ES, Ricklin D, Lambris JD, Hajishengallis G. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. Journal of Immunology (Baltimore, Md. : 1950). 189: 5442-8. PMID 23089394 DOI: 10.4049/Jimmunol.1202339 |
0.314 |
|
| 2012 |
DeAngelis RA, Reis ES, Ricklin D, Lambris JD. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology. 217: 1097-105. PMID 22964235 DOI: 10.1016/J.Imbio.2012.07.012 |
0.316 |
|
| 2012 |
Ricklin D. Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology. 217: 1057-66. PMID 22964231 DOI: 10.1016/J.Imbio.2012.07.016 |
0.448 |
|
| 2012 |
Ricklin D, Reis ES, Lambris JD. A sweet spot to control complement-induced inflammation. Nature Medicine. 18: 1340-1. PMID 22961162 DOI: 10.1038/Nm.2916 |
0.321 |
|
| 2012 |
Garcia BL, Summers BJ, Lin Z, Ramyar KX, Ricklin D, Kamath DV, Fu ZQ, Lambris JD, Geisbrecht BV. Diversity in the C3b [corrected] contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family. The Journal of Biological Chemistry. 287: 628-40. PMID 22086928 DOI: 10.1074/Jbc.M111.298984 |
0.394 |
|
| 2012 |
Garcia BL, Ramyar KX, Ricklin D, Lambris JD, Geisbrecht BV. Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins. Advances in Experimental Medicine and Biology. 946: 113-33. PMID 21948365 DOI: 10.1007/978-1-4614-0106-3_7 |
0.341 |
|
| 2012 |
Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement--their role in inflammation. Seminars in Immunopathology. 34: 151-65. PMID 21811895 DOI: 10.1007/S00281-011-0280-X |
0.366 |
|
| 2012 |
Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson B, Nilsson Ekdahl K, Ricklin D, Lambris JD. Protection of nonself surfaces from complement attack by factor H-binding peptides: Implications for therapeutic medicine (The Journal of Immunology (2011) 186, (4269-4277)) Journal of Immunology. 188: 6425. DOI: 10.4049/Jimmunol.1290027 |
0.332 |
|
| 2012 |
Risitano AM, Ricci P, Pascariello C, Raia M, Schmidt CQ, Li Y, Reis ES, Sica M, Notaro R, Del Vecchio L, Pane F, Ricklin D, Lambris JD. Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro Blood. 120: 370-370. DOI: 10.1182/Blood.V120.21.370.370 |
0.43 |
|
| 2012 |
Risitano AM, Ricci P, Pascariello C, Raia M, Schmidt CQ, Qu H, Ricklin D, Del Vecchio L, Pane F, Lambris JD. Peptide and protein inhibitors targeting the C3 convertase efficiently prevent surface C3 deposition and subsequent hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes Immunobiology. 217: 1217. DOI: 10.1016/J.Imbio.2012.08.251 |
0.365 |
|
| 2012 |
Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD. Rational engineering of a novel complement regulator-based therapeutic affords triple targeting of host surfaces and pathway-specific inhibition of complement activation Immunobiology. 217: 1197. DOI: 10.1016/J.Imbio.2012.08.195 |
0.357 |
|
| 2012 |
Stapels DA, Ramyar KX, Ricklin D, Milder FJ, Bischoff M, Herrmann M, Geisbrecht BV, Lambris JD, von Köckritz-Blickwede M, Kessel KPv, Rooijakkers SH. Extracellular adherence protein (Eap) of Staphylococcus aureus evades innate immunity by inhibiting complement activation and neutrophil elastase Immunobiology. 217: 1170. DOI: 10.1016/J.Imbio.2012.08.118 |
0.357 |
|
| 2012 |
Chen H, Ricklin D, Lambris JD. Compstatin induces allosteric changes in C3 and C3b and changes their ligand binding pattern Immunobiology. 217: 1160. DOI: 10.1016/J.Imbio.2012.08.089 |
0.302 |
|
| 2011 |
Ekdahl KN, Lambris JD, Elwing H, Ricklin D, Nilsson PH, Teramura Y, Nicholls IA, Nilsson B. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Advanced Drug Delivery Reviews. 63: 1042-50. PMID 21771620 DOI: 10.1016/J.Addr.2011.06.012 |
0.346 |
|
| 2011 |
Knerr PJ, Tzekou A, Ricklin D, Qu H, Chen H, Van Der Donk WA, Lambris JD. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin Acs Chemical Biology. 6: 753-760. PMID 21520911 DOI: 10.1021/Cb2000378 |
0.306 |
|
| 2011 |
Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson B, Nilsson Ekdahl K, Ricklin D, Lambris JD. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. Journal of Immunology (Baltimore, Md. : 1950). 186: 4269-77. PMID 21339361 DOI: 10.4049/Jimmunol.1003802 |
0.395 |
|
| 2011 |
Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Molecular Immunology. 48: 481-9. PMID 21067811 DOI: 10.1016/J.Molimm.2010.10.004 |
0.398 |
|
| 2010 |
Forneris F, Ricklin D, Wu J, Tzekou A, Wallace RS, Lambris JD, Gros P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science (New York, N.Y.). 330: 1816-20. PMID 21205667 DOI: 10.1126/Science.1195821 |
0.34 |
|
| 2010 |
Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, Ekdahl KN. Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. Plos One. 5: e12889. PMID 20886107 DOI: 10.1016/J.Molimm.2010.05.078 |
0.374 |
|
| 2010 |
Chen H, Ricklin D, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G, Wu YQ, Tzekou A, Li S, Geisbrecht BV, Woods VL, Lambris JD. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proceedings of the National Academy of Sciences of the United States of America. 107: 17621-6. PMID 20876141 DOI: 10.1073/Pnas.1003750107 |
0.442 |
|
| 2010 |
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nature Immunology. 11: 785-97. PMID 20720586 DOI: 10.1038/Ni.1923 |
0.349 |
|
| 2010 |
Garcia BL, Ramyar KX, Tzekou A, Ricklin D, McWhorter WJ, Lambris JD, Geisbrecht BV. Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b. Journal of Molecular Biology. 402: 17-29. PMID 20654625 DOI: 10.1016/J.Jmb.2010.07.029 |
0.451 |
|
| 2010 |
Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Lasaosa M, Wu Y, Lupu F, Kaznessis YN, Lambris JD. Generation of analogues of the clinical complement inhibitor compstatin with improved potency and pharmacokinetics Molecular Immunology. 47: 2289-2290. DOI: 10.1016/J.Molimm.2010.05.270 |
0.302 |
|
| 2010 |
Garcia BL, Tzekou A, Ricklin D, Ramyar KX, McWhorter WJ, Geisbrecht BV, Lambris JD. Molecular basis for complement recognition and inhibition by staphylococcal complement inhibitors Molecular Immunology. 47: 2245-2245. DOI: 10.1016/J.Molimm.2010.05.145 |
0.315 |
|
| 2010 |
Ricklin D, Chen H, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G, Wu Y, Tzekou A, Li S, Geisbrecht BV. Allosteric inhibition of complement function by the Staphylococcal immune evasion protein Efb Molecular Immunology. 47: 2244-2245. DOI: 10.1016/J.Molimm.2010.05.144 |
0.338 |
|
| 2009 |
Qu H, Ricklin D, Lambris JD. Recent developments in low molecular weight complement inhibitors. Molecular Immunology. 47: 185-95. PMID 19800693 DOI: 10.1016/J.Molimm.2009.08.032 |
0.396 |
|
| 2009 |
Stokmaier D, Khorev O, Cutting B, Born R, Ricklin D, Ernst TO, Böni F, Schwingruber K, Gentner M, Wittwer M, Spreafico M, Vedani A, Rabbani S, Schwardt O, Ernst B. Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R). Bioorganic & Medicinal Chemistry. 17: 7254-64. PMID 19762243 DOI: 10.1016/J.Bmc.2009.08.049 |
0.541 |
|
| 2009 |
Magotti P, Ricklin D, Qu H, Wu YQ, Kaznessis YN, Lambris JD. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. Journal of Molecular Recognition : Jmr. 22: 495-505. PMID 19658192 DOI: 10.1002/Jmr.972 |
0.382 |
|
| 2009 |
Ricklin D, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, Wu YQ, Holers VM, Herbert AP, Barlow PN, Geisbrecht BV, Lambris JD. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. Journal of Immunology (Baltimore, Md. : 1950). 183: 2565-74. PMID 19625656 DOI: 10.4049/Jimmunol.0901443 |
0.439 |
|
| 2009 |
Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nature Immunology. 10: 728-33. PMID 19503104 DOI: 10.1038/Ni.1755 |
0.383 |
|
| 2009 |
Rooijakkers SH, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJ, van Strijp JA, Gros P. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nature Immunology. 10: 721-7. PMID 19503103 DOI: 10.1038/Ni.1756 |
0.443 |
|
| 2009 |
Garcia BL, Tzekou A, Ramyar KX, McWhorter WJ, Ricklin D, Lambris JD, Geisbrecht BV. Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). Acta Crystallographica. Section F, Structural Biology and Crystallization Communications. 65: 482-5. PMID 19407382 DOI: 10.1107/S174430910901207X |
0.369 |
|
| 2009 |
Knecht S, Ricklin D, Eberle AN, Ernst B. Oligohis-tags: mechanisms of binding to Ni2+-NTA surfaces. Journal of Molecular Recognition : Jmr. 22: 270-9. PMID 19235144 DOI: 10.1002/Jmr.941 |
0.553 |
|
| 2008 |
Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Advances in Experimental Medicine and Biology. 632: 273-92. PMID 19025129 DOI: 10.1007/978-0-387-78952-1_20 |
0.421 |
|
| 2008 |
Ricklin D, Ricklin-Lichtsteiner SK, Markiewski MM, Geisbrecht BV, Lambris JD. Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. Journal of Immunology (Baltimore, Md. : 1950). 181: 7463-7. PMID 19017934 DOI: 10.4049/Jimmunol.181.11.7463 |
0.405 |
|
| 2008 |
Haspel N, Ricklin D, Geisbrecht BV, Kavraki LE, Lambris JD. Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d. Protein Science : a Publication of the Protein Society. 17: 1894-906. PMID 18687868 DOI: 10.1110/Ps.036624.108 |
0.354 |
|
| 2008 |
Schuster MC, Ricklin D, Papp K, Molnar KS, Coales SJ, Hamuro Y, Sfyroera G, Chen H, Winters MS, Lambris JD. Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Molecular Immunology. 45: 3142-51. PMID 18456336 DOI: 10.1016/J.Molimm.2008.03.010 |
0.336 |
|
| 2008 |
Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nature Reviews. Microbiology. 6: 132-42. PMID 18197169 DOI: 10.1038/Nrmicro1824 |
0.348 |
|
| 2008 |
Magotti P, Ricklin D, Sfyroera G, Qu H, Mollnes TE, Lupu F, Taylor FB, Lambris JD. A C3 inhibitor on its way to clinical applications: Novel developments in compstatin activity and function Molecular Immunology. 45: 4180. DOI: 10.1016/J.Molimm.2008.08.255 |
0.359 |
|
| 2008 |
Ricklin D, Ricklin-Lichtsteiner SK, Sfyroera G, Chen H, Tzekou A, Magotti P, Wu Y, Garcia BL, McWorther WJ, Haspel N, Kavraki LE, Geisbrecht BV, Lambris JD. Novel insights into target specificities and molecular mechanisms for two potent complement evasion proteins from Staphylococcus aureus Molecular Immunology. 45: 4114-4115. DOI: 10.1016/J.Molimm.2008.08.058 |
0.329 |
|
| 2007 |
Ricklin D, Lambris JD. Complement-targeted therapeutics. Nature Biotechnology. 25: 1265-75. PMID 17989689 DOI: 10.1038/Nbt1342 |
0.361 |
|
| 2007 |
Ricklin D, Lambris JD. Exploring the complement interaction network using surface plasmon resonance. Advances in Experimental Medicine and Biology. 598: 260-78. PMID 17892218 DOI: 10.1007/978-0-387-71767-8_19 |
0.364 |
|
| 2007 |
Hammel M, Sfyroera G, Pyrpassopoulos S, Ricklin D, Ramyar KX, Pop M, Jin Z, Lambris JD, Geisbrecht BV. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. The Journal of Biological Chemistry. 282: 30051-61. PMID 17699522 DOI: 10.1074/Jbc.M704247200 |
0.39 |
|
| 2007 |
Hammel M, Sfyroera G, Ricklin D, Magotti P, Lambris JD, Geisbrecht BV. A structural basis for complement inhibition by Staphylococcus aureus. Nature Immunology. 8: 430-7. PMID 17351618 DOI: 10.1038/Ni1450 |
0.422 |
|
| 2005 |
Herfurth L, Ernst B, Wagner B, Ricklin D, Strasser DS, Magnani JL, Benie AJ, Peters T. Comparative epitope mapping with saturation transfer difference NMR of sialyl Lewis(a) compounds and derivatives bound to a monoclonal antibody. Journal of Medicinal Chemistry. 48: 6879-86. PMID 16250646 DOI: 10.1021/Jm0502687 |
0.537 |
|
| Show low-probability matches. |